Insulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says

MT Newswires Live11-06 01:49

Insulet (PODD) long-term growth prospects remain attractive despite a more conservative revenue outlook, with valuation looking attractive given its growth profile, competitive advantages and expansion opportunities in the US Type 1 and Type 2 diabetes markets, RBC Capital Markets said.

The brokerage said in a Wednesday research note that the revised fiscal 2027 outlook reflects tougher comparisons, less pricing benefit outside the US and increased competition. However, it said that the competition does not change its investment thesis.

RBC highlighted Insulet's competitive advantages, including Omnipod's unique disposable pump design, established pharmacy-channel relationships and an affordable pay-as-you-go model.

It also sees opportunities from Type 2 diabetes market penetration, international expansion, continuous glucose monitor integrations and the planned Omnipod 6 launch in 2027.

RBC kept its outperform rating and raised its price target to $180 from $160.

The company's shares were down 6.1% in Thursday afternoon trading.

Price: 154.87, Change: -10.15, Percent Change: -6.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681537005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-06 01:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681537005","market":"fut","top_or_hot":-1,"title":"Insulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Insulet (PODD) long-term growth prospects remain attractive despite a more conservative revenue outlook, with valuation looking attractive given its growth profile, competitive advantages and expansion opportunities in the US Type 1 and Type 2 diabetes markets, RBC Capital Markets said.</p><p>The brokerage said in a Wednesday research note that the revised fiscal 2027 outlook reflects tougher comparisons, less pricing benefit outside the US and increased competition. However, it said that the competition does not change its investment thesis.</p><p>RBC highlighted Insulet's competitive advantages, including Omnipod's unique disposable pump design, established pharmacy-channel relationships and an affordable pay-as-you-go model.</p><p>It also sees opportunities from Type 2 diabetes market penetration, international expansion, continuous glucose monitor integrations and the planned Omnipod 6 launch in 2027.</p><p>RBC kept its outperform rating and raised its price target to $180 from $160.</p><p>The company's shares were down 6.1% in Thursday afternoon trading.</p><p>Price: 154.87, Change: -10.15, Percent Change: -6.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-11-06 01:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Insulet (PODD) long-term growth prospects remain attractive despite a more conservative revenue outlook, with valuation looking attractive given its growth profile, competitive advantages and expansion opportunities in the US Type 1 and Type 2 diabetes markets, RBC Capital Markets said.</p><p>The brokerage said in a Wednesday research note that the revised fiscal 2027 outlook reflects tougher comparisons, less pricing benefit outside the US and increased competition. However, it said that the competition does not change its investment thesis.</p><p>RBC highlighted Insulet's competitive advantages, including Omnipod's unique disposable pump design, established pharmacy-channel relationships and an affordable pay-as-you-go model.</p><p>It also sees opportunities from Type 2 diabetes market penetration, international expansion, continuous glucose monitor integrations and the planned Omnipod 6 launch in 2027.</p><p>RBC kept its outperform rating and raised its price target to $180 from $160.</p><p>The company's shares were down 6.1% in Thursday afternoon trading.</p><p>Price: 154.87, Change: -10.15, Percent Change: -6.15</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2681537005","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2681537005","pubTimestamp":1793900984,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Insulet  long-term growth prospects remain attractive despite a more conservative revenue outlook, with valuation looking attractive given its growth profile, competitive advantages and expansion opportunities in the US Type 1 and Type 2 diabetes markets, RBC Capital Markets said.The brokerage said in a Wednesday research note that the revised fiscal 2027 outlook reflects tougher comparisons, less pricing benefit outside the US and increased competition. However, it said that the competition does not change its investment thesis.RBC highlighted Insulet's competitive advantages, including Omnipod's unique disposable pump design, established pharmacy-channel relationships and an affordable pay-as-you-go model.It also sees opportunities from Type 2 diabetes market penetration, international expansion, continuous glucose monitor integrations and the planned Omnipod 6 launch in 2027.RBC kept its outperform rating and raised its price target to $180 from $160.The company's shares were down 6","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","PODD":"银休特","BK4551":"寇图资本持仓","BK4082":"医疗保健设备","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4566":"资本集团","BK4588":"碎股","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC"},"translate_title":"加拿大皇家银行表示，尽管 2027 年前景更加保守，但 Insulet 的估值仍有吸引力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":1.5},"content_text":"Insulet (PODD) long-term growth prospects remain attractive despite a more conservative revenue outlook, with valuation looking attractive given its growth profile, competitive advantages and expansion opportunities in the US Type 1 and Type 2 diabetes markets, RBC Capital Markets said.The brokerage said in a Wednesday research note that the revised fiscal 2027 outlook reflects tougher comparisons, less pricing benefit outside the US and increased competition. However, it said that the competition does not change its investment thesis.RBC highlighted Insulet's competitive advantages, including Omnipod's unique disposable pump design, established pharmacy-channel relationships and an affordable pay-as-you-go model.It also sees opportunities from Type 2 diabetes market penetration, international expansion, continuous glucose monitor integrations and the planned Omnipod 6 launch in 2027.RBC kept its outperform rating and raised its price target to $180 from $160.The company's shares were down 6.1% in Thursday afternoon trading.Price: 154.87, Change: -10.15, Percent Change: -6.15","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681537005","isCrawlerRequest":true}